NewGen Reports Nine-Month 2025 Results with Improved Net Asset Value Per Share to $66.75

NewGenIvf Group reported a net income of $17.5 million for the nine months ended September 30, 2025, compared to a net loss of $416,400 in the same period of 2024. Basic earnings per share was $96.76, and net book value per share improved to $66.75. The company completed two strategic acquisitions, including the MicroSort sperm-sorting technology and advanced cytometry intellectual property from Nodexus, and expanded into digital assets, including investing in Solana.